45th week of 2008 patent applcation highlights part 29 |
Patent application number | Title | Published |
20080274023 | Process for Reducing Fouling from Flash/Separation Apparatus during Cracking of Hydrocarbon Feedstocks - Hydrocarbon feedstock containing resid is cracked by a process comprising: (a) heating said hydrocarbon feedstock; (b) mixing the heated hydrocarbon feedstock with steam to form a mixture stream; (c) introducing the mixture stream to a flash/separation apparatus to form i) a vapor phase comprising coke precursors existing as uncoalesced condensate, and ii) a liquid phase; (d) removing the vapor phase as overhead and the liquid phase as bottoms from the flash/separation apparatus; (e) treating the overhead by contacting with a condensing means downstream of the flash/separation apparatus to at least partially coalesce the coke precursors to provide residue hydrocarbon liquid, and subsequently removing the hydrocarbon liquid; (f) heating the treated overhead to provide a heated vapor phase (g) cracking the heated vapor phase in a radiant section of a pyrolysis furnace to produce an effluent comprising olefins, the pyrolysis furnace comprising a radiant section and a convection section; and (h) quenching the effluent and recovering cracked product therefrom. An apparatus for carrying out the process is also provided. | 2008-11-06 |
20080274024 | Louver Front Faced Inlet Ducts - An apparatus is for directing a fluid into a radial reactor is and which maintains a bed of solid particulate material within a reactor. The apparatus comprises a duct for directing fluid into a reactor and has a screenless face for the egress of the fluid, while providing for the retention of solid particles. | 2008-11-06 |
20080274025 | Detergent Dispensing Device - A detergent dispensing device for an automatic washing machine, the device having a cartridge with a plurality of chambers to accommodate a detergent composition, a selecting means to selectively expose each chamber to wash liquor allowing the detergent, in use, to be washed out of the chamber; a manual operating means being movable from a first position to a second position for loading mechanical energy into the device which provides a restoring force for the operating means, and a thermal element to retain the operating means in the second position, the thermal element being arranged to move when subjected to an elevated temperature prevailing in an interior of the machine during a wash cycle, thereby moving the operating means or releasing the operating means, the operating means being arranged to advance the selecting means to an adjacent chamber as the cartridge remains stationary. | 2008-11-06 |
20080274026 | SELECTIVE PRECIPITATION OF METAL SULFIDES - A method for recovering zinc ions by selective zinc sulfide precipitation from an aqueous solution comprising zinc ions and metal ions of a metal that precipitates as a metal sulfide at a pH lower than a pH at which zinc ions precipitate as a zinc sulfide. | 2008-11-06 |
20080274027 | Pressure Leaching System and Method - A pressure leaching system for use in a leaching operation including: at least one reaction zone for receiving a slurry of material to be leached from a slurry source, the reaction zone being disposed relative to the slurry source such that slurry is resident in the reaction zone under gravity thereby providing at least part of the pressurisation required for the leaching operation. | 2008-11-06 |
20080274028 | Security pigments and the process of making thereof - Disclosed are methods for using color inconstancy pigments and/or dyes, such as rare earth doped color inconstancy pigments, in security applications including semi-overt and covert security application. | 2008-11-06 |
20080274029 | ORANGE-EMITTING PHOSPHOR - An orange-emitting phosphor that emits at a high luminance when being excited by blue light emitted by a blue light-emitting diode is provided. This orange-emitting phosphor is an alkaline-earth metal silicate-based phosphor represented by a general formula of a(Sr | 2008-11-06 |
20080274030 | Group III nitride compositions - The present invention provides compositions and a novel high-yielding process for preparing high purity Group III nitrides. The process involves heating a Group III metal and a catalytic amount of a metal wetting agent in the presence of a nitrogen source. Group III metals can be stoichiometrically converted into high purity Group III nitride powders in a short period of time. The process can provide multi-gram quantities of high purity Group III nitrides in relatively short reaction times. Detailed characterizations of GaN powder were performed and are reported herein, including morphology and structure by SEM and XRD, optical properties by cathodoluminescence (CL), and Raman spectra to determine the quality of the GaN particles. The purity of GaN powder was found to be greater than 99.9% pure, as analyzed by Glow Discharge Mass Spectrometry (GDMS). Green, yellow, and red light emission can be obtained from doped GaN powders. | 2008-11-06 |
20080274031 | Method for Producing High Purity Silicon - The invention relates to a method for producing a great deal of inexpensive high purity silicon useful in a solar battery. Disclosed is a method for producing high purity silicon by removing boron from silicon by oxidization including commencing an oxidization reaction between an oxidizing agent and molten silicon, and cooling at least part of the oxidizing agent during the reaction. | 2008-11-06 |
20080274032 | Method for Isolating N2o - The present invention relates to a process for purifying a gas mixture G-0 comprising dinitrogen monoxide, at least comprising the absorption of the gas mixture G-0 in an organic solvent, subsequent desorption of a gas mixture G-1 from the laden organic solvent, absorption of the gas mixture G-1 in water and subsequent desorption of a gas mixture G-2 from the laden water, and also to the use of a purified gas mixture which comprises dinitrogen monoxide and is obtainable by such a process as an oxidizing agent for olefins. | 2008-11-06 |
20080274033 | Methods of generating hydrogen with nitrogen-containing hydrogen storage materials - Methods of generating hydrogen-containing streams having a minimal concentration of gaseous reactive nitrogen-containing compounds, e.g., ammonia, are provided. Hydrogen storage material systems are also provided that generate such hydrogen-containing streams. A first composition comprising a nitride, a second composition comprising a hydride, and a third composition having a cation selected from the group consisting of: alkali metals, alkaline earth metals, and mixtures thereof are combined together. The hydrogen-containing stream thus generated has a minimal concentration of gaseous reactive nitrogen-containing compounds. | 2008-11-06 |
20080274034 | PROCESS FOR PREPARING MULTIMETALLIC ANIONIC CLAYS AND PRODUCTS THEREOF - Multimetallic anionic clays (MACs) are prepared using economical raw materials or reactants and a procedure for obtaining a series of multimetallic mixed oxides derived from the thermal decomposition of the MACs which comprises: (1) dissolving water-soluble bimetallic and/or trimetallic sources in water, (2) dispersing and homogenizing separate water-insoluble divalent and/or trivalent metal precursors with a high-speed stirrer in order to obtain small and reactive particles; depending on the nature of the water-insoluble divalent and/or trivalent metal precursors, this process can be adjusted to a desired pH, (3) adding the suspension obtained in (2) to solution (1) with the reaction medium still dispersed to facilitate solid particle's reduction/dissociation, and (4) afterwards the slurry is aged for several hours and finally dried. This process enables raw materials or reactants to be easily handled, and eliminates unit operations involving product washing and/or purification steps. | 2008-11-06 |
20080274035 | REVERSIBLE OXIDATION OF CARBON NANOTUBES - Carbon nanotubes have been reversibly and readily oxidized and reduced with common chemicals in solution, thereby allowing the nanotubes to be used as catalysts for chemical reactions and as stable charge storage devices. | 2008-11-06 |
20080274036 | MICROSTRUCTURED CATALYSTS AND METHODS OF USE FOR PRODUCING CARBON NANOTUBES - Methods for producing microstructured catalytic substrates and microstructured catalytic substrates produced by the methods, and methods for growing single-walled carbon nanotubes on the microstructured catalytic substrates wherein the single-walled carbon nanotubes are preferably of a highly specific chirality. | 2008-11-06 |
20080274037 | Method For The Preparation Of X-Ray Amorphous Or Weakly Crystalline Metal Oxide Fluorides And New Uses Thereof - The present invention is related to a method for preparing an X-ray amorphous or weakly crystalline metal oxide fluoride of a composition represented by the formula M | 2008-11-06 |
20080274038 | Flow Control Device, Microreactor and Use Thereof - A microreactor containing a plurality of introduction channels | 2008-11-06 |
20080274039 | Integrated electrochemical and thermochemical renewable energy production, storage, distribution and recycling system - A first aspect of the present invention is a self-contained electrolysis process. The process includes utilizing a cryogenic cogeneration process to extract a liquid from an atmospheric medium, passing a current through the liquid, and separating at least one chemical element from the liquid. A second aspect of the present invention is a self-contained electrolysis apparatus. The apparatus includes cryogenic cogeneration means for extracting a liquid from an atmospheric medium, electrical means for passing a current through the liquid and separating means for separating at least one chemical compound from the liquid. A third aspect of the present invention is a method and system of removing at least one element from a chemical compound. The method and system include utilizing a cryogenic cogeneration process to remove the at least one element from the chemical compound. | 2008-11-06 |
20080274040 | Injector assembly, chemical reactor and chemical process - An injector assembly for injecting an additional component into a component stream flowing through a reactor conduit along the longitudinal axis thereof. A chemical reactor including an injector assembly for injecting an additional component into a moving component stream and a chemical process are also provided. In one embodiment, the chemical process is a process for producing titanium dioxide. | 2008-11-06 |
20080274041 | Preparation of nanoparticle-size zinc compounds - A method for making a dispersion of zinc oxide particles in hydrocarbon is provided. A zinc compound that thermally disintegrates is dispersed in a hydrocarbon solvent with a selected organic acid and the mixture is heated to a temperature range to cause the zinc compound to thermally disintegrate into nano-sized particles. | 2008-11-06 |
20080274042 | Nanostructured Zinc Oxide and a Method of Producing the Same - A method of producing nanostructured zinc oxide powder. The method comprises introducing a source of zinc selected from metallic zinc or zinc compound and a process gas mixture which includes an oxidizing gas (the reactants) into a reactor. While in the reactor, the reactants are heated to a process temperature effective to vaporize the zinc and to react the reactants to form a powder product. The powder product is recovered. | 2008-11-06 |
20080274043 | Contact and adsorbent granules - The present invention relates to a filtering unit at least partially filled with particles agglomerated from fine-particle iron oxide and/or iron oxyhydroxide by producing an aqueous suspension of fine-particle iron oxides and/or iron oxyhydroxides having a BET surface area of 50 to 500 m | 2008-11-06 |
20080274044 | Methods of administering liquid droplet aerosols of nanoparticulate drugs - There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol. | 2008-11-06 |
20080274045 | Imaging, diagnosis and treatment of disease - The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium. | 2008-11-06 |
20080274046 | Radiolabelling - Compounds of the formula (I) are disclosed: | 2008-11-06 |
20080274047 | Compositions and Methods for Treating Proliferative Disorders - The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology. | 2008-11-06 |
20080274048 | CONJUGATES OF ANTIOXIDANTS WITH METAL CHELATING LIGANDS FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes. | 2008-11-06 |
20080274049 | Cytotoxicity mediation of cells evidencing surface expression of CD44 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention. | 2008-11-06 |
20080274050 | Labelled Adrenomedullin Derivatives and Their Use for Imaging and Therapy - The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such us for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus. | 2008-11-06 |
20080274051 | Diagnosis and Treatment of Mood Disorders - The present invention relates to the diagnosis, treatment and monitoring of mood disorders. For example, a diagnosis may be performed by determining whether a monoamine oxidase in a vertebrate is elevated compared to a healthy control subject. Methods of monitoring treatments and methods for identifying treatments for mood disorders are also provided. | 2008-11-06 |
20080274052 | RADIOFLORINATION METHODS - The present invention relates to methods and reagents for [ | 2008-11-06 |
20080274053 | TISSUE METABOLIC STRESS MONITORING - Various pathophysiological states are determined by evaluating the rate of | 2008-11-06 |
20080274054 | Composite for Thermo-Sensitive Cell-Tissue Transplanted Scaffold and Use thereof - A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. This invention also provides a method of treating a subject with a skin defect by covering the composite of the present invention on the skin defect of the subject in need of such treatment. Furthermore, using this composite with different growth factors, stem cells can be induced to differentiate into skin-related, neuronal cells, neuron, and insulin-positive cells in biodegradable scaffolds as well as transplanted graft. Finally, this invention also provides a quick and convenient method of monitoring cell growth or tissue engineering in an animal. | 2008-11-06 |
20080274055 | Framework Residue Substituted Humanized Col-1 Antibodies and Their Use - The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein. | 2008-11-06 |
20080274056 | NANOPARTICLE DELIVERY SYSTEMS FOR MEMBRANE-INTEGRATING PEPTIDES - Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid/surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described. | 2008-11-06 |
20080274057 | Staudinger Reaction in Imaging and Therapy and Kits for Use in Imaging and Therapy - The Staudinger reaction can be used for activation of prodrugs or pro-imaging probes. The invention relates to a method of preparing and activating prodrugs or pro-imaging probes by using the Staudinger reaction and to kits for medical imaging and/or therapy comprising at least one prodrug and/or pro-imaging probe comprising at least one azide and/or phosphine group. | 2008-11-06 |
20080274058 | Isotopically-Labeled Benzofuran Compounds as Imaging Agents for Amyloidogenic Proteins - Benzofuran compounds which contain at least one detectable label selected from the group consisting of | 2008-11-06 |
20080274059 | MITE FUSION PROTEINS - The present invention relates to fusion proteins comprising a Group I allergen and a Group II allergen from the genus | 2008-11-06 |
20080274060 | Therapeutic Foam - A foam is described for injection treatment of varicose veins. The foam comprises a sclerosant liquid, e.g. polidocanol solution, and a gas. The gas comprises xenon, optionally together with at least one other physiologically acceptable gas which is readily absorbed in the body or blood of a patient. The gas comprises only a minimal amount of gaseous nitrogen, between 0.0001% and 0.8%. | 2008-11-06 |
20080274061 | Method for Treating a Restless Limb Disorder - A method for treating a restless limb disorder such as restless legs syndrome in a subject comprises administering, transmucosally in the oronasopharyngeal chamber of the subject, one or more doses of rotigotine or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein each such dose comprises an amount effective to reduce occurrence and/or severity of one or more symptoms of the disorder, but wherein the total of all such doses in a 24-hour period does not exceed about | 2008-11-06 |
20080274062 | Glycyrrhizic acid compounds as a foamer in chemically-derived surfactant-free dentifrice - The present invention relates to dentifrices in general and dentifrices free of chemically-derived foaming agents in particular. Particularly, the present invention relates to an all-natural dentifrice (e.g., toothpaste) comprising a concentration of glycyrrhizic acid that is suitable to work as a foaming agent. Even more particularly, the present invention relates to an all-natural dentifrice (e.g., toothpaste) that does not contain one or more of sodium lauryl sulfate, sodium lauroyl sarcosinate, cocomidopropyl betaine, sodium methyl cocoyl taurate, sodium cocoyl glutamate, poloxamer or any other chemically-derived foaming agent. | 2008-11-06 |
20080274063 | Supercritical CO2 liquorice extract anti-microbial and anti-inflammatory isolates and products made there from - The present invention provides, in one aspect, to products made from a novel and non-obvious supercritical CO | 2008-11-06 |
20080274064 | UTILIZATION OF RHINOLOGICALLY ACTIVE SUBSTANCES - Acyclic compounds containing an ethers functionality external to the ring can be used as rhinologically active substances. In the regions of the mouth, the throat and the airways they produce a refreshing and clearing feeling. | 2008-11-06 |
20080274065 | Oral Care Regimen - The invention includes methods of cleaning an oral surface, maintaining oral health and/or increasing oral health. Such methods encompass contacting an oral surface with a primary oral care composition at least once daily, contacting the oral surface with a periodic oral care maintenance composition at least once monthly, wherein the periodic oral care maintenance composition comprises a basic amino acid, in free or salt form and optionally contacting the oral surface with a periodic oral care cleaning composition at least once monthly. The periodic oral care cleaning compositions suitable for use in the method comprise an abrasive system. | 2008-11-06 |
20080274066 | Compositions, Methods, Devices, and Kits for Maintaining or Enhancing Tooth Whitening - Compositions, methods, devices, and kits for maintaining or enhancing tooth whitening in a subject are disclosed. The methods include applying a first tooth whitening composition to the teeth of the subject for a predetermined period of time and applying a second tooth whitening composition to the teeth of the subject in predetermined intervals, wherein at least one of the first and second tooth whitening compositions are dispensed from a dental delivery device. The kits include a first tooth whitening composition and a second tooth whitening composition, each including an oxidizing agent. The oxidizing agent of the first tooth whitening composition is present in a higher amount than the second tooth whitening composition, which maintains or enhances the tooth whitening effect of the first tooth whitening composition. | 2008-11-06 |
20080274067 | Tooth Whitening Composition - An oral care composition comprising an active agent e.g. a whitening agent and a carrier including a carrier base comprising a wax and a substantivity agent. A method of whitening the teeth using the composition is also disclosed. | 2008-11-06 |
20080274068 | External Preparation for Skin Containing a Phosphorlated Saccharide - Provided is an external preparation for skin, comprising a phosphorylated saccharide. The phosphorylated saccharide may be an inorganic salt of a phosphorylated saccharide. The phosphorylated saccharide may be a calcium, magnesium, potassium, zinc, iron or sodium salt. Also provided is an external preparation for skin, comprising a phosphorylated saccharide and a second component, wherein the second component is selected from the group consisting of moisturizing agents, whitening components, ultraviolet absorbents, anti-inflammatory agents, cell-activating agents and antioxidants. The moisturizing agent may be ascorbic acid or an ascorbic acid derivative. | 2008-11-06 |
20080274069 | Cosmetic Preparations Containing Copolymers of Ethyl Methacrylate and at Least One Monoethylenically Unsaturated Carboxylic Acid - Copolymers prepared by a process comprising free-radical polymerizing: (a) more than 15 to 40% by weight of at least one monoethylenically unsaturated carboxylic acid; (b) 30 to less than 85% by weight of ethyl methacrylate; and (c) 0 to 50% by weight of at least one additional free-radically polymerizable monomer other than the at least one monoethylenically unsaturated carboxylic acid and ethyl methacrylate; wherein the total amount of (a), (b) and (c) equals 100% by weight; with the proviso that where the process comprises a solution polymerization, (a) consists of acrylic acid and methacrylic acid, and (c) is an ester of (meth)acrylic acid and an aliphatic C | 2008-11-06 |
20080274070 | Method for permanently reshaping keratin fibers comprising applying a poorly concentrated reducing compositions followed by drying - The present disclosure relates to a method for permanently reshaping the keratin fibers, for example permanently reshaping the hair, comprising:
| 2008-11-06 |
20080274071 | POWDERY STYLING AGENTS AND THE DISPENSER SYSTEMS THEREOF - The present invention relates to agents for the setting and styling of keratin fibers, in particular human hair, from a suitable dispenser system in the form of a fine powder, which is optionally freshly ground, shaved or rasped only directly prior to use, and to the use of this preparation for the treatment of keratin fibers, in particular human hair. | 2008-11-06 |
20080274072 | Insect repellants and insecticides - An insect repellant is in a sprayable gel formulation. The insect repellant is citronella based and may contain a deodorizer. An insecticide is in a sprayable gel formulation and may contain a deodorizer. | 2008-11-06 |
20080274073 | Process for Producing Aqueous Emulsions and Dispersions - The use of terpolymers, obtainable by free radical copolymerization of
| 2008-11-06 |
20080274074 | Method for Controlled Free Radical Polymerization or Copolymerization of Methacrylic and/or Methacrylate Monomers or Exclusively Methacrylic and/or Methacrylate Copolymers - The invention relates to a method for the polymerization of one or more methacrylate and/or methacrylic monomers, for the synthesis of methacrylate or methacrylic polymers or of exclusively methacrylic and/or methacrylate copolymers, comprising a step of bringing said monomer(s) into contact with one at least of the compounds of formula (I) and (II) below: | 2008-11-06 |
20080274075 | Poly(Ethylene Glycol) Derivatives and Process For Their Coupling to Proteins - Novel compounds, including PEGylated proteins of the formula, methods for preparing such compounds, methods of using such compounds, and other compositions and methods, are provided. | 2008-11-06 |
20080274076 | Composition for Use in Controlling Aedes Aegypti Mosquitoes - The present invention discloses a composition for use in luring | 2008-11-06 |
20080274077 | Method for Treating Neurological Disorders - The present invention is based on the discovery that suppressing the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration unless the intrinsic growth program of neurons is also activated Accordingly, the present invention is directed to methods of stimulating axon regeneration using a combination therapy wherein agents that inhibit NgR activity or downstream pathways activated by inhibitory signals are combined with agents that activate the growth pathway of neurons (e.g. polypeptide growth factors, activators of macrophages, purine nucleosides, or hexoses). | 2008-11-06 |
20080274078 | NOVEL USES - The present invention relates generally to the use of human IL-18 combinations in the treatment of cancers. In particular, the present invention relates to combination of human IL-18 and an anti-CD20 antibody. | 2008-11-06 |
20080274079 | De novo synthesis of glucocorticoids in the epidermis and its uses and applications - The present invention relates to methods and compositions that control, i.e., antagonize/inhibit or agonize/stimulate, de novo glucocorticoid production in the skin. Such methods and compositions can be used for the prevention and/or treatment of a variety of skin conditions, including inflammation, acute wounds, chronic non-healing wounds, keloid, fibrotic or hypertrophic scars, and epithelial-derived cancer. | 2008-11-06 |
20080274080 | AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 2008-11-06 |
20080274081 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines. | 2008-11-06 |
20080274082 | OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 2008-11-06 |
20080274083 | Antiviral Resistance Mutants and Applications Thereof - The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus. | 2008-11-06 |
20080274084 | Anti-Tnf Alpha Producing Lactic Acid Bacteria for the Treatment of Chronic Enterocolitis - Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as | 2008-11-06 |
20080274085 | Probiotic Bifidobacterial Species - A probiotic composition comprising a | 2008-11-06 |
20080274086 | Use of Cxcr4 Protein Expression on the Surface of Stem Cells as a Marker for Tumor Tropic Potential - The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1. | 2008-11-06 |
20080274087 | BRAIN TISSUE DAMAGE THERAPIES - A cultured pluripotent animal cell that is CD13+, CD90+, and CD117−. Also disclosed are methods for making the cell and methods of treating a brain tissue damage and increasing the expression level of a neuraltrophic factor in a subject. | 2008-11-06 |
20080274088 | Mapc Generation of Lung Tissue - The present invention relates to methods of improving function in lung tissue by administering a population of multipotent adult progenitor cells (“MAPCs”) or differentiated progeny thereof. | 2008-11-06 |
20080274089 | Inflammation - This invention provides adult neural stem cell (aNSC) materials and methods for treating central nervous system disorders. | 2008-11-06 |
20080274090 | REVERSAL OF INSULIN-DEPENDENT DIABETES BY ISLET-PRODUCING STEM CELLS, ISLET PROGENITOR CELLS AND ISLET-LIKE STRUCTURES - The subject invention concerns new methods which make it possible, for the first time, to grow functional islet-producing stem cells (IPSCs), islet progenitor cells (IPCs) and IPC-derived islets (IdIs) in in vitro cultures. The subject invention also concerns the use of the in vitro grown IPSCs, IPCs and/or IdIs for implantation into a mammal for in vivo therapy of diabetes. The subject invention further concerns a process of using the implanted cells for growing a pancreas-like structure in vivo that has the same functional, morphological and histological characteristics as those observed in normal pancreatic endocrine tissue. The ability to grow these cells in vitro and pancreas-like structures in vivo opens up important new avenues for research and therapy relating to diabetes. | 2008-11-06 |
20080274091 | Autologous T Cell Manufacturing Processes - The invention provides novel processes for manufacturing autologous T cells, transducing T cells and expanding the transduced T cell population. | 2008-11-06 |
20080274092 | Erythrocytes Containing Arginine Deiminase - Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. Said use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention and/or treatment of septic shock. | 2008-11-06 |
20080274093 | METHOD OF DIMINISHING THE SYMPTOMS OF NEURODEGENERATIVE DISEASE - A method of diminishing the symptoms of neurodegenerative disease in a patient is disclosed. In one embodiment, the method comprises the steps of: (a) identifying a patient with a neurodegenerative disease, (b) producing a cell culture, wherein the cell culture comprises cells with induced antioxidant response element (ARE) mediated transcription, and (c) transplanting at least a portion of the cell culture into the brain of the patient, wherein symptoms of neurodegenerative disease are diminished. | 2008-11-06 |
20080274094 | Molecular Complex Comprising Arbutine, Ascorbic Acid, Oleuropeina or Its Derivatives Thereof and Related Uses In Medical Field - The present invention relates to a molecular complex comprising arbutine, ascorbic acid, oleuropeina or its derivatives and related uses in medical field, for example for the treatment of the skin, mucosa and serosa, for the treatment of skin aging, cutaneous hyperpigmentation and skin diseases. | 2008-11-06 |
20080274095 | Biocides - The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification). | 2008-11-06 |
20080274096 | Fusion Proteins Having a Modulated Half-Life in Plasma - The present invention relates to fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein comprises a component that cleaves the amyloid beta (Ab) peptide e.g. neprilysin, insulin degrading enzyme (IDE), another component that modulates the half-life in plasma e.g. the Fc portion of IgG or PEG; and a third component that connects the first two components. | 2008-11-06 |
20080274097 | BOOSTER FOR THERAPY OF DISEASES WITH ULTRASOUND AND PHARMACEUTICAL LIQUID COMPOSITION CONTAINING THE SAME - A booster comprising a plurality of microbubbles of a gas in a liquid, e.g. about 4×10 | 2008-11-06 |
20080274098 | Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to a Neuro-, Muscular- or Neuro-Muscular-Degenerative Disease, or Restore Tissue Adversely Affected by Said Disease - A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in the tissue. | 2008-11-06 |
20080274099 | ANTIBODIES OF THE ED-B DOMAIN OF FIBRONECTIN, THEIR CONSTRUCTION AND USES - According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members. | 2008-11-06 |
20080274100 | ANTIBODIES AND USES THEREOF - The present invention provides antibodies or fragments thereof that bind to co-receptor CCR5 or CXCR4. | 2008-11-06 |
20080274101 | STABILIZING POLYPEPTIDES WHICH HAVE BEEN EXPOSED TO UREA - Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea. | 2008-11-06 |
20080274102 | Antibodies to Nik, Their Preparation and Use - An antibody or antibody fragment preparation being capable of specifically binding the amino acid sequence 60-76, 86-98, 135-149, 215-227, 363-377, 385-397, 405-419, 427-440, 509-522, 605-619, 635-649, 666-680, 696-711, 752-766, 836-851, 871-884, and/or 904-916 of NIK, or being capable of specifically binding a specific portion of the amino acid sequence is provided. | 2008-11-06 |
20080274103 | Adenylyl Cyclase Antibodies, Compositions and Uses Thereof - The invention relates to compositions and methods for diagnosing and treating cardiac conditions and neurodegenerative diseases using antibodies which specifically recognize and bind to the adenylyl cyclase 5 isoform in the heart and brain. These antibodies demonstrate high specificity to the AC5 isoform and do not cross react to any other AC5 isoform. The invention further relates to methods of delivery of drugs to the site of injured tissue using the antibodies of the present invention. | 2008-11-06 |
20080274104 | Targeting a Secreted Pro-Apoptotic Factor for Cancer Therapeutics - The present invention concerns targeting a cell death factor associated with cancer. More specifically, an apoptosis-inducing factor is targeted to prevent destruction of non-cancerous cells. The factor may be a lipocalin molecule, and in specific embodiments its secretion and/or the secreted form is targeted by an inhibitory agent, such as an antibody, small molecule, antisense RNA, or siRNA, for example. | 2008-11-06 |
20080274105 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 2008-11-06 |
20080274106 | Mesothelioma therapeutic agent - The present invention provides a mesothelioma therapeutic agent containing an interleukin-6 (IL-6) antagonist such as antibody to IL-6 receptor (IL-6R), and a mesothelioma cell growth inhibitor containing an IL-6 antagonist such as antibody to IL-6R. | 2008-11-06 |
20080274107 | Tyrosine kinase inhibitors - The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals. | 2008-11-06 |
20080274108 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 2008-11-06 |
20080274109 | Myeloid Progenitor Inhibitory Factor-1 (MPIF-1), Monocyte Colony Inhibitory Factor (M-CIF), and Macrophage Inhibitory Factor-4 (MIP-4) - There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine β8 (CKβ8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-γ and chemokine β1 (CKβ1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. | 2008-11-06 |
20080274110 | Cell Death-Inducing Agents - To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. As a result, the 2D7 antibody was found to recognize HLA class IA. In addition, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents. | 2008-11-06 |
20080274111 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 2008-11-06 |
20080274112 | Nogo Receptor Antagonists - Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. | 2008-11-06 |
20080274113 | Method and Compositions for Prevention and Treatment of Malaria Infections - Isolated proteins and nucleic acid sequence encoding such protein that interacts with a red blood cell to be invaded by a malaria parasite and link with a component of the actin-myosin based machinery of the malaria parasite are provided. In addition methods for identifying agents which inhibit the function of these proteins as chemotherapeutic and/or immunologic agents for treatment and prevention of malaria infections are provided. Compositions for treatment and prevention of malaria infections and methods for preventing and treating malaria infections are also provided. | 2008-11-06 |
20080274114 | Anti-Egfr Antibodies - The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers. | 2008-11-06 |
20080274115 | Soluble ErbB3 Methods of Detection and Antibodies - Regulation of sErbB3 isoforms in methods of regulating heregulin activity or ErbB receptor activities is disclosed. Cancer therapeutics and methods of therapeutically treating cancer comprising sErbB3 are also disclosed. Detection of sErbB3 in biological samples for risk assessment and prevention, screening, diagnosis, prognosis, theragnosis, evaluation of responsiveness to treatment, and/or monitoring of disease progression, recurrence, or metastasis of a cancer is disclosed as well. In examples, sErbB3 nucleic acid sequences, polypeptides, molecular probes, and antibodies are useful agents for regulation, expression, detection, and cancer therapeutics related to sErbB3. | 2008-11-06 |
20080274116 | Lipids, Lipid Complexes and Use Thereof - The present invention is related to a compound according to formula (I), wherein R | 2008-11-06 |
20080274117 | Validation of Tssk Family Members and Tsks as Male Contraceptive Targets - The present invention relates to a family of testis specific kinases (the TSSK family) and a substrate (TSKS) of TSSK, nucleic acid sequences encoding those kinases and substrate, and antibodies and antagonists against the kinases and substrate, methods of regulating these proteins, and their use as contraceptive targets. | 2008-11-06 |
20080274118 | Methods for Diagnosis and Treatment of Diseases Having an Autoimmune and/or Inflammatory Component - Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent. | 2008-11-06 |
20080274120 | Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent - The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin®, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount. | 2008-11-06 |
20080274121 | Inhibition of Angiogenesis by Mithramycin - We disclose a method of inhibiting angiogenesis in a mammal by administering by a subcutaneous or intraperitoneal route to a tissue in the mammal where angiogenesis is occurring a composition comprising mithramycin and a pharmaceutically-acceptable carrier. We have found a subcutaneous or intraperitoneal dose from about 10 μg mithramycin per kg body weight per day to about 500 μg mithramycin per kg body weight per day can be effective for inhibition of angiogenesis. | 2008-11-06 |
20080274122 | Plks as Modifiers of the Beta Catenin Pathway and Methods of Use - Human PLK genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of PLK are provided. | 2008-11-06 |
20080274123 | Specific Binding Members Against Synaptophysin - The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11; and/or an antibody VL domain selected front the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated it liver fibrosis. | 2008-11-06 |